Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

This study has been completed.

Sponsor:

Information provided by:

GlobeImmune

ClinicalTrials.gov Identifier:

NCT00124215

First received: July 25, 2005

Last updated: May 3, 2010

Last verified: May 2010

History of Changes

Purpose

The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.

Condition	Intervention	Phase
Hepatitis C	Biological: GI-5005	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment
Official Title:	A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection

Resource links provided by NLM:

MedlinePlus related topics: Hepatitis Hepatitis A Hepatitis C

U.S. FDA Resources

Further study details as provided by GlobeImmune:

Primary Outcome Measures:

Safety and tolerability [ Time Frame: 1 year ]


Estimated Enrollment:	48
Study Start Date:	June 2005
Study Completion Date:	February 2010
Primary Completion Date:	June 2007 (Final data collection date for primary outcome measure)

Intervention Details:

Heat-killed yeast cell transfected with NS3-Core fusion protien.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy
>18 years of age
Negative skin test for hypersensitivity to saccharomyces cerevisiae.

Exclusion Criteria:

Non-responders to previous interferon treatments
Cirrhosis
HCV treatment within 3 months
Hepatitis B infection
HIV infection

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00124215

Locations


United States, California
Huntington Medical Research Institutes
Pasadena, California, United States, 91105
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80262
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, New York
Weill Medical College of Cornell University
New York City, New York, United States, 10021

Sponsors and Collaborators

GlobeImmune

More Information

Additional Information:

Sponsor's website This link exits the ClinicalTrials.gov site


Responsible Party:	John Ferraro, MBA Director Clinical Operations, GlobeImmune, Inc.
ClinicalTrials.gov Identifier:	NCT00124215 History of Changes
Other Study ID Numbers:	GI-5005-01
Study First Received:	July 25, 2005
Last Updated:	May 3, 2010

Keywords provided by GlobeImmune:


Hepatitis HCV vaccine Hepatitis C Infection

Additional relevant MeSH terms:


Infection Hepatitis Hepatitis A Hepatitis C Hepatitis, Chronic Hepatitis C, Chronic Liver Diseases	Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections

ClinicalTrials.gov processed this record on September 21, 2017

To Top